Trial reportBMC ophthalmology2023
Suprachoroidal injection of triamcinolone acetonide plus intravitreal bevacizumab in diabetic macular edema: a randomized pilot trial.
Trial report in BMC ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and clinical outcomes of suprachoroidal triamcinolone acetonide in diabetic macular edema patients: a single-arm systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Pooled it
- Pooled it
- Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis.Frontiers in endocrinology · 2024Pooled it
- Comparison of Efficacy of Suprachoroidal Triamcinolone Acetonide Alone or in Combination With Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema: A Prospective Comparative Study.Health science reports · 2026Article
- Suprachoroidal Triamcinolone Plus Intravitreal Bevacizumab Versus Bevacizumab Alone for Diabetic Macular Edema in Pseudophakic Eyes: A randomized controlled trial.Pakistan journal of medical sciences · 2026Article
- Advances in microneedle Technology for Treatment of retinal degenerative diseases: a narrative review.Biomedical microdevices · 2026Review
- Suprachoroidal injection in the treatment of diabetic macular edema: mechanisms, clinical advances, and future perspectives.Frontiers in medicine · 2026Review
- Mechanistic Insights into the Combined Anti-inflammatory Effects of Bevacizumab and Triamcinolone in Hyperglycemic Retinal Cells: Modulation of MCP-1, CXCL10, and Their Receptors.Journal of ophthalmic & vision research · 2026Article
- Bevacizumab and beyond: investigating the role of combination therapies in the management of retinal diseases.International ophthalmology · 2025Review
- What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series.International journal of retina and vitreous · 2024Article
- Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the efficacy of injecting suprachoroidal triamcinolone acetonide (SCTA) plus intravitreal bevacizumab (IVB) into patients with center-involving diabetic macular edema (CI-DME).
methodsIn this phase 2/3 randomized controlled pilot trial, sixty-six eyes with CI-DME and best-corrected visual acuity (BCVA) of at most 20/50 Snellen chart were randomly assigned into two groups. Monotherapy arm received sham injection plus 3 monthly IVB doses and combination arm received a single dose of SCTA and 3 monthly IVB doses. The mean improvements in BCVA and Central subfield thickness (CST), over the three-month was considered the main efficacy outcomes.
resultsThe mean BCVA improvements were obtained respectively as - 0.20 ± 0.20 log [minimum angle of resolution (MAR)] (P = 0.004) and 0.37 ± 0.24 log MAR (P < 0.001) in monotherapy and combination arms [between-group analysis (P = 0.014)]. Significant improvements were also observed in CST (P = 0.019) in the combination arm compared to the other. No adverse events (elevated intraocular pressure, cataract) were observed in any of the study arms.
conclusionSignificant improvements in BCVA and retinal anatomical outcomes demonstrated the additive effects of SCTA to those of anti-vascular endothelial growth factors with no short-term side effects and this combination appears to be a promising option in the management of patients with CI-DME.
trial registrationThe trial was registered in Iranian Registry of Clinical Trials (IRCT20200314046761N1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.